UNSPSC 51293015: Nortriptyline hydrochloride

This classification denotes an adrenergic uptake inhibitor and tricyclic antidepressive agent with the molecular formula C19H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 00FN6IH15D, chemically known as 10,11-dihydro-n-methyl-5h-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine but more generally known as nortriptyline hydrochloride, which bears US NIH Compound Identifier 4543.

UNSPSC 51293015 Nortriptyline hydrochloride, a Commodity code, nominally names a specific antidepressant pharmaceutical; however, recent state and local solicitations tagged under this code actually procure a much broader range of pharmaceuticals and drug-related supplies. State and local health departments, cooperative purchasing alliances, and county health systems use this code to source generic multi-source pharmaceuticals, over-the-counter products, emergency medications such as naloxone, and drug deactivation systems. The work ranges from establishing master supply agreements with manufacturers through authorized wholesalers to spot purchases of specific pharmaceutical inventories for community health and emergency response programs. Issuing bodies include state health and human services agencies (notably Texas HHS and Minnesota Department of Administration), county government health systems (Seminole County, Florida), and interstate cooperative purchasing vehicles such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which coordinate procurement across multiple participating jurisdictions.

Recent activity spans multiple states and procurement approaches. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with a March 26, 2026 response deadline and July 1, 2026 contract effective date. Seminole County, Florida posted an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline. The Texas Health and Human Services Commission issued a Request for Information in April 2026 to gather vendor capabilities on direct-to-manufacturer pharmacy programs. These opportunities reflect demand across Florida, Texas, Minnesota, and participating MMCAP jurisdictions including Oregon; the code sees activity predominantly from state agency procurement offices and health-focused county governments conducting either cooperative or individual competitive solicitations.